

Pharmaceutical Pipeline – Key Events in 2018*

Potential Approvals US/EU	ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (US) ✓	Potential Clinical Data Presentations	XARELTO® – VTE prevention medically ill pts (MARINER) ✓
	JULUCA® (Rilpivirine+ dolutegravir FDC ViiV) – HIV (EU) ✓		– Congestive heart failure (COMMANDER) ✓
	SYMTUZA™ – HIV (US) ✓		STELARA® – Ulcerative Colitis (UNIFI) ✓
	DARZALEX® – Frontline multiple myeloma non-transplant (US /EU) ✓		Esketamine Nasal spray – Treatment-resistant depression ✓
	XARELTO® – CAD/PAD (US) ✓		ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (SPARTAN) ✓
	INVOKANA® – CANVAS/CANVAS-R–CV outcome (US / EU) ✓		SYMTUZA™ – HIV ✓
	ZYTIGA® – Hormone-naïve metastatic prostate cancer (US) ✓		IMBRUVICA® – Frontline CLL combo w/obinutuzumab (ILLUMINATE) ✓
	IMBRUVICA® – Waldenström’s macroglobulinemia in combo w/rituximab (US) ✓		– Treatment-naïve WM combo w/rituximab (iINNOVATE) ✓
TREMFYA® – Psoriasis Patient-Controlled Injector (EU) ✓	DARZALEX® – Frontline Multiple Myeloma transplant ineligible in combo w/ lenalidomide and low dose dexamethasone (MAIA) ✓		
Planned Submissions US/EU	Esketamine Nasal Spray – Treatment-resistant depression (US / EU) ✓	Phase 3	TREMFYA – Psoriasis, H2H (ECLIPSE) ✓
	Erdafitinib – Urothelial cancer (US) ✓		
	ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (EU) ✓		
	IMBRUVICA® – Frontline CLL combo w/obinutuzumab (US / EU) ✓		
	– Waldenström’s macroglobulinemia combo w/rituximab (US / EU) ✓		
	OPSUMIT® – Chronic thromboembolic PH (US /EU) ✓		
	TREMFYA® – Psoriasis Patient-Controlled Injector (US / EU) ✓		
	STELARA® – Ulcerative Colitis (US / EU) ✓		
XARELTO® – VTE prevention medically ill pts (MARINER) (US) ✓			
Potential Clinical Data Presentations	Phase 2	HIV Vaccine – HIV (TRAVERSE) ✓	
		IMBRUVICA® – DLBCL relapsed (PCYC1123) ✓	
		– Frontline CLL (IV fixed duration) (PCYC1142) ✓	
		DARZALEX® – Frontline multiple myeloma transplant (GRIFFIN) MRD and safety ✓	
		Erdafitinib – Metastatic urothelial cancer (BLC2001) ✓	

✓ = Achieved

* This information is accurate as of January 22, 2019 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.